Nanos Medical Raises Over RMB300m to Boost Otolaryngology Device Lead
China-based Nanos Medical (Shanghai) Limited, an otolaryngology device maker, has reportedly raised over RMB300 million...
Finance
StairMed Raises Record RMB350m for Implantable BCI Development
Shanghai StairMed Technology Co., Ltd., a specialist in implantable brain-computer interface (BCI) technology, has reportedly...
Anhui Anke to Invest in Visen Pharma’s Hong Kong IPO as Cornerstone Investor
China – based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced its plan...
Novartis to Acquire Anthos Therapeutics for $3.1B, Boosting Factor XI Inhibitor Portfolio
Swiss pharma giant Novartis (NYSE: NVS) announced plans to acquire Anthos Therapeutics, Inc., a cardiometabolic-focused...
R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech
Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD...
Xtalpi Invests in Alternative Bio for Cancer and Inflammation Drugs
Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced a strategic investment in...
CR Sanjiu Gains SASAC Approval for Tasly Pharma Acquisition
China-based CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company, has received approval from the State-owned...
Regeneron’s Q4 Financials Show 10% Revenue Growth, Driven by Eylea and Libtayo
US-based biopharmaceutical company Regeneron (NASDAQ: REGN) released its Q4 2024 financial report, showing revenues up...
Tofflon to Join Shanghai Biomedical M&A Fund with Leading Firms
China-based Tofflon Science and Technology Group Co., Ltd. (SHE: 300171), a total solution service provider...
PegBio’s Lead Product PB-119 Clears HKEX Hearing for Type 2 Diabetes and Obesity Treatment
On January 28, 2025, the Hong Kong Stock Exchange (HKEX) website showed that PegBio Co.,...
Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model
On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita...
Jiangsu Yuyue Partners with Inogen for International Distribution and R&D
China-based Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SHE: 002223) has struck a partnership...
Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing
Jiangsu Vcare PharmaTech Co., Ltd., a China – based high – tech pharmaceutical company, has...
ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline
ConjuStar, a specialist in X-Drug conjugates (XDCs) based in Tianjin, has reportedly raised RMB100 million...
iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies
Hangzhou-based cell therapy specialist iMBIORAY has reportedly raised close to RMB 100 million (USD 13.7...
Shenzhen TargetRx Raises $50M in Series C Financing for Global Clinical Trials
China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, has announced the completion of...
Degron Therapeutics Secures $20M Series A+ for Molecular Glue Drug Development
China-based Degron Therapeutics, a specialist in molecular glue-based drugs, has reportedly raised over USD 20...
NAMSA to Acquire WuXi AppTec’s US Medical Device Testing Business
US-based medical device contract research organization (CRO) NAMSA is set to acquire the medical device...
Inscinstech Secures C-Series Financing for Biopharma Expansion
Inscinstech Co., Ltd., a leading intelligent technology company based in Suzhou, has successfully completed a...
Raytone Bio Completes Angel Round to Advance iSus® Platform
Raytone Bio, a Shenzhen-based biopharmaceutical company, has announced the completion of a multi-million RMB Angel...